MD, FRCPC (Internal Medicine), BSc Pharm
PO Box 6058
Vancouver BC V6H 4B9
Complex Pain & Cannabinoid Clinician, Researcher, Educator
- Department of Medicine, Faculty of Medicine, Division of Community Internal Medicine, University of British Columbia (UBC)
- Department of Medicine, Faculty of Medicine, Division of Palliative Care, UBC
- Faculty of Pharmaceutical Sciences, UBC
- Greenleaf Medical Clinic
Dr. Caroline MacCallum is a specialist in internal medicine, with expertise in complex pain and cannabinoid medicine. She is a clinical instructor in the Department of Medicine; Adjunct Professor in the Faculty of Pharmaceutical Sciences program; and associate member in the Dept. of Palliative Care at the University of British Columbia.
Dr. MaCallum is the medical director of Greenleaf Medical Clinic, where she has assessed and developed cannabinoid treatment plans for more than 5,000 patients using legal medical cannabis approved by Health Canada.
Caroline MacCallum is the primary author of Practical Considerations for Medical Cannabis Administration and Dosing, published in the European Journal of Medicine, which has been cited over 250 times. She is the assistant editor for the upcoming Cannabinoids and Pain book by Springer; and first author on eight chapters pertaining to cannabis pharmacovigilance including: mental health, impairment, dosing, patient safety (contraindications & drug interactions), product safety, pain, and cannabis-opioid synergy.
Dr. MacCallum has presented internationally on the topic of cannabis dosing, safety and polypharmacy reduction/substitution. She has qualified as a medical cannabis expert and testified in arbitration for a claim involving a challenge to Health Canada’s 24-hour rule for cannabis impairment. Dr. MacCallum is currently working with university research groups, hospitals, health benefit programs, provincial and national committees to create; guidelines, safe prescribing practices, clinical trials, patient registries and adverse event monitoring.
Her research interests include: cannabis and psychedelics as adjuvants to standard of care and for deprescribing/drug substitution; pharmacovigilance and impairment; and symptomatic and functional improvement in complex conditions with particular focus on fibromyalgia, chronic fatigue, PTSD, TBI and chronic pain.
Narouze SN, MacCallum CA. eds. Cannabinoids and Pain. Springer; 2021
Duration of neurocognitive impairment with medical cannabis use: a scoping review. Frontiers in Psychiatry. 2021 – https://doi.org/10.3389/fpsyt.2021.638962
Canadian clinical practice guidelines for the use of plant-based cannabis and cannabinoid-based products in the management of chronic non-cancer pain and co-occurring conditions: protocol for a systematic literature review. BMJ Open. 2020;10:e036114 – http://dx.doi.org/10.1136/bmjopen-2019-036114
Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments. BMC Psychiatry. 2019;19:335 – https://doi.org/10.1186/s12888-019-2324-z
Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine. 2018;49 – https://doi.org/10.1016/j.ejim.2018.01.004